:: CLDF ::

Pathophysiology of NASH in endocrine diseases

Endocr Connect. 2021 Jan 1;EC-20-0490.R1. doi: 10.1530/EC-20-0490.Online ahead of print.

Karim Gariani¹, François R Jornayvaz²

Adherence to Ideal Cardiovascular Health Metrics Is Associated With Reduced Odds of Hepatic Steatosis

Hepatol Commun. 2020 Oct 10;5(1):74-82. doi: 10.1002/hep4.1614. eCollection 2021 Jan.

Leah R DeCoste¹, Na Wang², Joseph N Palmisano², Jean Mendez³, Udo Hoffmann⁴, Emelia J Benjamin^5 6 7, Michelle T Long³

Association of liver enzymes with incident diabetes in US Hispanic/Latino adults

Diabet Med. 2021 Jan 12;e14522. doi: 10.1111/dme.14522. Online ahead of print.

Simin Hua¹, Qibin Qi¹, Jorge R Kizer², Jessica Williams-Nguyen³, Howard D Strickler¹, Bharat Thyagarajan⁴, Martha Daviglus⁵, Gregory A Talavera⁶, Neil Schneiderman⁷, Scott J Cotler⁸, Jianwen Cai⁹, Robert Kaplan^1 3, Carmen R Isasi¹

Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease

Diagnostics (Basel). 2021 Jan 9;11(1):E98. doi: 10.3390/diagnostics11010098.

Stefano Ballestri¹, Alessandro Mantovani², Enrica Baldelli³, Simonetta Lugari⁴, Mauro Maurantonio⁴, Fabio Nascimbeni⁴, Alessandra Marrazzo¹, Dante Romagnoli⁵, Giovanni Targher², Amedeo Lonardo⁶

Liver Fat Quantification by Ultrasound in Children: A Prospective Study

AJR Am J Roentgenol. 2021 Jan 13. doi: 10.2214/AJR.20.24874. Online ahead of print.

Aurélie D'Hondt¹, Erika Rubesova¹, Hua Xie², Vijay Shamdasani³, Richard A Barth¹

Metabolic associated fatty liver disease: Addressing a new era in liver transplantation

World J Hepatol. 2020 Dec 27;12(12):1168-1181. doi: 10.4254/wjh.v12.i12.1168

Madeleine G Gill¹, Avik Majumdar¹

Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping

J Med Internet Res. 2021 Jan 15;23(1):e20491. doi: 10.2196/20491.

Kate Hallsworth^1 2 3, Stuart McPherson^1 2 3, Quentin M Anstee^1 2 3, Darren Flynn⁴, Laura Haigh^1 2 3, Leah Avery^3 4

Ceramide Salvage, Gut Mucosal IgA Signaling, and Diet-Induced NASH

Hepatology. 2021 Jan 15. doi: 10.1002/hep.31707. Online ahead of print.

Scott A McHenry¹, Nicholas O Davidson¹

Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease

Transl Gastroenterol Hepatol. 2021 Jan 5;6:3. doi: 10.21037/tgh.2020.02.18.eCollection 2021.

Eric K Kwong¹, Puneet Puri^2 3

10.

Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry

Transl Gastroenterol Hepatol. 2021 Jan 5;6:5. doi: 10.21037/tgh.2020.01.04.eCollection 2021.

Amon Asgharpour¹, Amreen Dinani¹, Scott L Friedman¹

11.

Maternal Diet Alters Trained Immunity in the Pathogenesis of Pediatric NAFLD

J Cell Immunol. 2020;2(6):315-325. doi: 10.33696/immunology.2.061.

Karen R Jonscher^1 2, Jesse Abrams², Jacob E Friedman^2 3

12.

Non-alcoholic Fatty Liver and Liver Fibrosis Predictive Analytics: Risk Prediction and Machine Learning Techniques for Improved Preventive Medicine

J Med Syst. 2021 Jan 11;45(2):22. doi: 10.1007/s10916-020-01693-5.

Orit Goldman¹, Ofir Ben-Assuli², Ori Rogowski³, David Zeltser³, Itzhak Shapira³, Shlomo Berliner³, Shira Zelber-Sagi^4 5, Shani Shenhar-Tsarfaty³

13.

Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis

Obes Surg. 2021 Jan 6. doi: 10.1007/s11695-020-05084-0. Online ahead of print.

Saurabh Chandan¹, Babu P Mohan², Shahab R Khan³, Antonio Facciorusso⁴, Daryl Ramai⁵, Lena L Kassab⁶, Neil Bhogal⁷, Ravishankar Asokkumar⁸, Gortrand Lopez-Nava⁸, Stephanie McDonough², Douglas G Adler⁹

14.

Dietary approaches to managing nonalcoholic fatty liver disease

Nurse Pract. 2020 Dec 31;Publish Ahead of Print. doi: 10.1097/01.NPR.0000731560.23509.ff.Online ahead of print.

Dalia El Khoury¹, Rosemary J Pauley, Carol Lynn Berseth

15.

Lean NAFLD: an underrecognized and challenging disorder in medicine

Rev Endocr Metab Disord. 2021 Jan 3. doi: 10.1007/s11154-020-09621-1.Online ahead of print.

Sheila Maier¹, Amanda Wieland², Melanie Cree-Green³, Kristen Nadeau³, Shelby Sullivan⁴, Miguel A Lanaspa⁵, Richard J Johnson⁵, Thomas Jensen^6 7

16.

Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis

World J Hepatol. 2020 Nov 27;12(11):993-1003. doi: 10.4254/wjh.v12.i11.993.

Catherine J Choi¹, Stanley H Weiss², Umair M Nasir¹, Nikolaos T Pyrsopoulos³

17.

Insulin Resistance is Mechanistically Linked to Hepatic Mitochondrial Remodeling in Nonalcoholic Fatty Liver Disease

Mol Metab. 2020 Dec 22;101154. doi: 10.1016/j.molmet.2020.101154. Online ahead of print.

Chris E Shannon¹, Mukundan Ragavan², Juan Pablo Palavicini³, Marcel Fourcaudot¹, Terry Bakewell¹, Ivan A Valdez¹, Iriscilla Ayala¹, Eunsook S Jin⁴, Muniswamy Madesh⁵, Xianlin Han⁶, Matthew E Merritt², Luke Norton⁷

18.

Glycogenosis is Common in Nonalcoholic Fatty Liver Disease and is Independently Associated with Ballooning, but Lower Steatosis and Lower Fibrosis

Liver Int. 2020 Dec 22. doi: 10.1111/liv.14773. Online ahead of print.

Daniela S Allende¹, Samer Gawrieh², Oscar W Cummings³, Patricia Belt⁴, Laura Wilson⁴, Mark Van Natta⁴, Cynthia A Behling⁵, Danielle Carpenter⁶, Ryan M Gill⁷, David E Kleiner⁸, Mathew M Yeh⁹, Naga Chalasani², Cynthia D Guy¹⁰, NASH Clinical Research Network

19.

Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steato-hepatitis: a hierarchical network meta-analysis

Diabetes Obes Metab. 2020 Dec 23. doi: 10.1111/dom.14304. Online ahead of print.

Simona Panunzi¹, Sabina Maltese², Ornella Verrastro^3 4, Luca Labbate², Andrea De Gaetano¹, Maurizio Pompili^3 4, Esmeralda Capristo^3 4, Stefan R Bornstein^5 6, Geltrude Mingrone^3 4 6

20.

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

Front Endocrinol (Lausanne). 2020 Dec 14;11:601290.doi: 10.3389/fendo.2020.601290. eCollection 2020.

Erik J Tillman¹, Tim Rolph¹

21.

Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study

Patient. 2020 Dec 18. doi: 10.1007/s40271-020-00485-w. Online ahead of print.

Lynda C Doward¹, Maria-Magdalena Balp², James Twiss³, Christina Slota⁴, Donna Cryer⁵, Clifford A Brass⁶, Quentin M Anstee^7 8, Arun J Sanyal⁹

22.

Metabolic drivers of non-alcoholic fatty liver disease

Mol Metab. 2020 Dec 17;101143. doi: 10.1016/j.molmet.2020.101143. Online ahead of print.

Kendra K Bence¹, Morris J Birnbaum²

23.

Incidence of Depression and Anxiety in a Cohort of Adolescents with Nonalcoholic Fatty Liver Disease

J Pediatr Gastroenterol Nutr. 2020 Dec 16;Publish Ahead of Print.doi: 10.1097/MPG.0000000000003024. Online ahead of print.

Sheila Noon¹, Danielle D'Annibale, Melanie Schwimmer, Jacqueline Shiels, Jennifer Arin, Janis Durelle, Kimberly Newton, Nidhi Goyal, Jeffrey Schwimmer

24.

Evaluation of Non-Alcoholic Fatty Liver Disease in Pediatric Patients with Inflammatory Bowel Disease

J Pediatr Gastroenterol Nutr. 2020 Dec 16;Publish Ahead of Print.doi: 10.1097/MPG.0000000000003023. Online ahead of print.

Mallory E Cohen¹, Parakkal Deepak, Geetika Khanna, Charles M Samson

25.

Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis

World J Gastroenterol. 2020 Dec 14;26(46):7367-7381. doi: 10.3748/wjg.v26.i46.7367.

Peter Hoffmann¹, Victoria Jung², Rouven Behnisch³, Annika Gauss²